Clinical TrialApr 17, 2026, 04:02 PM
Acrivon's ACR-368 & ACR-2316 Show Strong Preclinical Synergy
AI Summary
Acrivon Therapeutics announced positive preclinical data for its lead assets, ACR-368 and ACR-2316, demonstrating strong synergistic effects with established anti-cancer agents. ACR-368 showed potent efficacy in combination with anti-PD-L1 and Topoisomerase 1 (Topo 1) inhibitors, while ACR-2316 synergized with anti-PD-L1. These findings support the potential for future frontline clinical development of these combinations, offering new therapeutic avenues. The data will be presented at the AACR 2026 Annual Meeting.
Key Highlights
- ACR-368 showed synergy with anti-PD-L1 and Topo 1 inhibitors.
- ACR-2316 demonstrated synergy with anti-PD-L1 checkpoint inhibition.
- Data supports potential for frontline clinical combinations.
- Findings to be presented at AACR 2026 Annual Meeting.
Price Impact
More from ACRV